A comparative, randomized, open label clinical study to assess the efficacy and safety of topical prednisolone acetate 1%, dexamethasone 0.1%, loteprednol etabonate 0.5% and difluprednate 0.05% eye drops in postoperative ocular inflammation following cataract surgery.

Dr DINKAR BERI0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects with senile cataract with an indication for cataract extraction.
•2.Subjects willing to give informed consent and be available for regular follow up.

•1.Subjects with congenital and traumatic cataract.
•2.Subjects with recurrent infectious and/or inflammatory eye diseases.
•3.Subjects with uncontrolled diabetes or associated with complications.
•4.Subjects with history of auto-immune diseases.
•5.Subjects who are immunocompromised or having tuberculosis, human immunodeficiency virus (HIV) infection.
•6.Subjects who develop intra-operative complications during surgery.
•7.Subjects with history of hypersensitivity to study drugs.
•8.Subjects with history of steroid use 14 days prior to surgery.
•9.Subjects with active ocular and/or ENT infections.
•10.Subjects with uncontrolled glaucoma.

发起方

Dr DINKAR BERI